Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maristella Bungaro

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Treatment Options in Oncology|November 17, 2022
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has BegunMaristella Bungaro, Silvia Novello, Francesco Passiglia
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathwaysMaristella Bungaro, Consuelo Buttigliero, Marcello Tucci
Biomedicines|April 23, 2022
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to RecoveryMaristella Bungaro, Francesco Passiglia, Giorgio V Scagliotti
Future Oncology (London, England)|March 14, 2022
Single agent VS-6766 or VS-6766 plus defactinib in <i>KRAS</i>-mutant non-small-cell lung cancer: the RAMP-202 phase II trialEnrica Capelletto, Paolo Bironzo, Louis Denis, et al.
Tumori|November 11, 2021
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case reportFabio Turco, Marcello Tucci, Rosario Francesco Di Stefano, et al.
Endocrine-Related Cancer|May 5, 2021
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCCFabio Turco, Marcello Tucci, Rosario Francesco Di Stefano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic reviewClizia Zichi, Chiara Paratore, Piera Gargiulo, et al.
Minerva Urology and Nephrology|February 11, 2022
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective studyTiziana Angusti, Rosario F DI Stefano, Antonella Parente, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2021
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetateRosario F Di Stefano, Marcello Tucci, Fabio Turco, et al.
Minerva Urology and Nephrology|March 30, 2021
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamideChiara Pisano, Marcello Tucci, Rosario F DI Stefano, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Treatment Options in Oncology|November 17, 2022
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has BegunMaristella Bungaro, Silvia Novello, Francesco Passiglia
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathwaysMaristella Bungaro, Consuelo Buttigliero, Marcello Tucci
Biomedicines|April 23, 2022
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to RecoveryMaristella Bungaro, Francesco Passiglia, Giorgio V Scagliotti
Future Oncology (London, England)|March 14, 2022
Single agent VS-6766 or VS-6766 plus defactinib in <i>KRAS</i>-mutant non-small-cell lung cancer: the RAMP-202 phase II trialEnrica Capelletto, Paolo Bironzo, Louis Denis, et al.
Tumori|November 11, 2021
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case reportFabio Turco, Marcello Tucci, Rosario Francesco Di Stefano, et al.
Endocrine-Related Cancer|May 5, 2021
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCCFabio Turco, Marcello Tucci, Rosario Francesco Di Stefano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic reviewClizia Zichi, Chiara Paratore, Piera Gargiulo, et al.
Minerva Urology and Nephrology|February 11, 2022
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective studyTiziana Angusti, Rosario F DI Stefano, Antonella Parente, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2021
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetateRosario F Di Stefano, Marcello Tucci, Fabio Turco, et al.
Minerva Urology and Nephrology|March 30, 2021
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamideChiara Pisano, Marcello Tucci, Rosario F DI Stefano, et al.
Pageof 2